Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Suppression of Ser/Thr phosphatase 4 (PP4C/PPP4C) mimics a novel post-mitotic action of fostriecin, producing mitotic slippage followed by tetraploid cell death.

Theobald B, Bonness K, Musiyenko A, Andrews JF, Urban G, Huang X, Dean NM, Honkanen RE.

Mol Cancer Res. 2013 Aug;11(8):845-55. doi: 10.1158/1541-7786.MCR-13-0032. Epub 2013 May 13.

2.

Antisense inhibition of connective tissue growth factor (CTGF/CCN2) mRNA limits hypertrophic scarring without affecting wound healing in vivo.

Sisco M, Kryger ZB, O'Shaughnessy KD, Kim PS, Schultz GS, Ding XZ, Roy NK, Dean NM, Mustoe TA.

Wound Repair Regen. 2008 Sep-Oct;16(5):661-73. doi: 10.1111/j.1524-475X.2008.00416.x.

PMID:
19128261
3.

Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity.

Graff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D, Weir SN, Schwier P, Capen A, Goode RL, Dowless MS, Chen Y, Zhang H, Sissons S, Cox K, McNulty AM, Parsons SH, Wang T, Sams L, Geeganage S, Douglass LE, Neubauer BL, Dean NM, Blanchard K, Shou J, Stancato LF, Carter JH, Marcusson EG.

J Clin Invest. 2007 Sep;117(9):2638-48.

4.

Selective down-regulation of glioma-associated oncogene 2 inhibits the proliferation of hepatocellular carcinoma cells.

Kim Y, Yoon JW, Xiao X, Dean NM, Monia BP, Marcusson EG.

Cancer Res. 2007 Apr 15;67(8):3583-93.

5.
6.

Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance.

Carter BZ, Mak DH, Shi Y, Schober WD, Wang RY, Konopleva M, Koller E, Dean NM, Andreeff M.

Cell Cycle. 2006 Oct;5(19):2223-9. Epub 2006 Oct 1.

PMID:
16969080
7.

Competition for RISC binding predicts in vitro potency of siRNA.

Koller E, Propp S, Murray H, Lima W, Bhat B, Prakash TP, Allerson CR, Swayze EE, Marcusson EG, Dean NM.

Nucleic Acids Res. 2006;34(16):4467-76. Epub 2006 Aug 31.

8.

Laparoscopic colposuspension for urinary incontinence in women.

Dean NM, Ellis G, Wilson PD, Herbison GP.

Cochrane Database Syst Rev. 2006 Jul 19;(3):CD002239. Review.

PMID:
16855989
9.
10.

Use of a chemically modified antisense oligonucleotide library to identify and validate Eg5 (kinesin-like 1) as a target for antineoplastic drug development.

Koller E, Propp S, Zhang H, Zhao C, Xiao X, Chang M, Hirsch SA, Shepard PJ, Koo S, Murphy C, Glazer RI, Dean NM.

Cancer Res. 2006 Feb 15;66(4):2059-66.

11.

Defining the transcriptome of accelerated and replicatively senescent keratinocytes reveals links to differentiation, interferon signaling, and Notch related pathways.

Perera RJ, Koo S, Bennett CF, Dean NM, Gupta N, Qin JZ, Nickoloff BJ.

J Cell Biochem. 2006 May 15;98(2):394-408.

PMID:
16440318
12.

Identification of novel PPARgamma target genes in primary human adipocytes.

Perera RJ, Marcusson EG, Koo S, Kang X, Kim Y, White N, Dean NM.

Gene. 2006 Mar 15;369:90-9. Epub 2005 Dec 27.

PMID:
16380219
13.

Protein phosphatase 5 is required for ATR-mediated checkpoint activation.

Zhang J, Bao S, Furumai R, Kucera KS, Ali A, Dean NM, Wang XF.

Mol Cell Biol. 2005 Nov;25(22):9910-9.

14.
15.

Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs.

Sun Y, Koo S, White N, Peralta E, Esau C, Dean NM, Perera RJ.

Nucleic Acids Res. 2004 Dec 22;32(22):e188.

16.

MicroRNA-143 regulates adipocyte differentiation.

Esau C, Kang X, Peralta E, Hanson E, Marcusson EG, Ravichandran LV, Sun Y, Koo S, Perera RJ, Jain R, Dean NM, Freier SM, Bennett CF, Lollo B, Griffey R.

J Biol Chem. 2004 Dec 10;279(50):52361-5. Epub 2004 Oct 25.

17.

Setting sights on the treatment of ocular angiogenesis using antisense oligonucleotides.

Henry SP, Marcusson EG, Vincent TM, Dean NM.

Trends Pharmacol Sci. 2004 Oct;25(10):523-7. Review.

PMID:
15380936
18.

Constitutive over expression of serine/threonine protein phosphatase 5 (PP5) augments estrogen-dependent tumor growth in mice.

Golden T, Aragon IV, Zhou G, Cooper SR, Dean NM, Honkanen RE.

Cancer Lett. 2004 Nov 8;215(1):95-100.

PMID:
15374638
19.

Use of antisense oligonucleotides in functional genomics and target validation.

Ravichandran LV, Dean NM, Marcusson EG.

Oligonucleotides. 2004 Spring;14(1):49-64. Review.

PMID:
15104896
20.
21.

Requirement of protein phosphatase 5 in DNA-damage-induced ATM activation.

Ali A, Zhang J, Bao S, Liu I, Otterness D, Dean NM, Abraham RT, Wang XF.

Genes Dev. 2004 Feb 1;18(3):249-54.

22.

Antisense oligonucleotide-based therapeutics for cancer.

Dean NM, Bennett CF.

Oncogene. 2003 Dec 8;22(56):9087-96. Review.

PMID:
14663487
23.

Mediation of transforming growth factor-beta(1)-stimulated matrix contraction by fibroblasts: a role for connective tissue growth factor in contractile scarring.

Daniels JT, Schultz GS, Blalock TD, Garrett Q, Grotendorst GR, Dean NM, Khaw PT.

Am J Pathol. 2003 Nov;163(5):2043-52.

24.
25.

Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia.

Carter BZ, Milella M, Tsao T, McQueen T, Schober WD, Hu W, Dean NM, Steelman L, McCubrey JA, Andreeff M.

Leukemia. 2003 Nov;17(11):2081-9.

PMID:
12970762
26.

Antisense oligonucleotide inhibition of Bcl-xL and Bid expression in liver regulates responses in a mouse model of Fas-induced fulminant hepatitis.

Zhang H, Taylor J, Luther D, Johnston J, Murray S, Wyatt JR, Watt AT, Koo S, York-DeFalco C, Stecker K, Dean NM.

J Pharmacol Exp Ther. 2003 Oct;307(1):24-33. Epub 2003 Jul 31.

PMID:
12893848
27.

Oligonucleotide inhibition of Fas as a potential treatment strategy in human liver disease.

Zhang H, Dean NM.

Drug News Perspect. 2001 Oct;14(8):453-9.

PMID:
12806430
28.

Novel antisense oligonucleotides targeting TGF-beta inhibit in vivo scarring and improve surgical outcome.

Cordeiro MF, Mead A, Ali RR, Alexander RA, Murray S, Chen C, York-Defalco C, Dean NM, Schultz GS, Khaw PT.

Gene Ther. 2003 Jan;10(1):59-71.

PMID:
12525838
29.

Identification of a functional link for the p53 tumor suppressor protein in dexamethasone-induced growth suppression.

Urban G, Golden T, Aragon IV, Cowsert L, Cooper SR, Dean NM, Honkanen RE.

J Biol Chem. 2003 Mar 14;278(11):9747-53. Epub 2003 Jan 7.

30.

Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis.

Vickers TA, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF.

J Biol Chem. 2003 Feb 28;278(9):7108-18. Epub 2002 Dec 23.

31.

The protein kinase C beta II exon confers mRNA instability in the presence of high glucose concentrations.

Patel NA, Eichler DC, Chappell DS, Illingworth PA, Chalfant CE, Yamamoto M, Dean NM, Wyatt JR, Mebert K, Watson JE, Cooper DR.

J Biol Chem. 2003 Jan 10;278(2):1149-57. Epub 2002 Oct 28.

32.

Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.

Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL, Bataille R, Amiot M.

Blood. 2002 Jul 1;100(1):194-9.

PMID:
12070027
33.
35.

Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice.

Butler M, McKay RA, Popoff IJ, Gaarde WA, Witchell D, Murray SF, Dean NM, Bhanot S, Monia BP.

Diabetes. 2002 Apr;51(4):1028-34.

36.

Use of antisense oligonucleotides: advantages, controls, and cardiovascular tissue.

Golden T, Dean NM, Honkanen RE.

Microcirculation. 2002 Jan;9(1):51-64. Review.

PMID:
11896559
37.

In vitro and in vivo downregulation of MRP1 by antisense oligonucleotides: a potential role in neuroblastoma therapy.

Kuss BJ, Corbo M, Lau WM, Fennell DA, Dean NM, Cotter FE.

Int J Cancer. 2002 Mar 1;98(1):128-33.

38.

Functional genomics and target validation approaches using antisense oligonucleotide technology.

Dean NM.

Curr Opin Biotechnol. 2001 Dec;12(6):622-5. Review.

PMID:
11849945
39.

Inhibition of Bcl-xL expression sensitizes T-cell acute lymphoblastic leukemia cells to chemotherapeutic drugs.

Broome HE, Yu AL, Diccianni M, Camitta BM, Monia BP, Dean NM.

Leuk Res. 2002 Mar;26(3):311-6.

PMID:
11792421
40.

Serine/threonine protein phosphatase 5 (PP5) participates in the regulation of glucocorticoid receptor nucleocytoplasmic shuttling.

Dean DA, Urban G, Aragon IV, Swingle M, Miller B, Rusconi S, Bueno M, Dean NM, Honkanen RE.

BMC Cell Biol. 2001;2:6. Epub 2001 May 17.

41.

Identification of an estrogen-inducible phosphatase (PP5) that converts MCF-7 human breast carcinoma cells into an estrogen-independent phenotype when expressed constitutively.

Urban G, Golden T, Aragon IV, Scammell JG, Dean NM, Honkanen RE.

J Biol Chem. 2001 Jul 20;276(29):27638-46. Epub 2001 Apr 30.

42.
43.

p27Kip1 is required for PTEN-induced G1 growth arrest.

Gottschalk AR, Basila D, Wong M, Dean NM, Brandts CH, Stokoe D, Haas-Kogan DA.

Cancer Res. 2001 Mar 1;61(5):2105-11.

44.

In vivo suppression of Bcl-XL expression facilitates chemotherapy-induced leukaemia cell death in a SCID/NOD-Hu model.

Fennell DA, Corbo MV, Dean NM, Monia BP, Cotter FE.

Br J Haematol. 2001 Mar;112(3):706-13.

PMID:
11260076
45.

Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice.

Yu RZ, Zhang H, Geary RS, Graham M, Masarjian L, Lemonidis K, Crooke R, Dean NM, Levin AA.

J Pharmacol Exp Ther. 2001 Feb;296(2):388-95.

PMID:
11160622
46.

Antisense oligonucleotides as research tools.

Taylor JK, Cooper SR, Dean NM.

Methods Mol Med. 2001;61:99-106. doi: 10.1385/1-59259-145-0:99.

PMID:
22323254
47.

Inhibition of PDK-1 activity causes a reduction in cell proliferation and survival.

Flynn P, Wongdagger M, Zavar M, Dean NM, Stokoe D.

Curr Biol. 2000 Nov 16;10(22):1439-42.

48.
49.

5' phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells.

Taylor V, Wong M, Brandts C, Reilly L, Dean NM, Cowsert LM, Moodie S, Stokoe D.

Mol Cell Biol. 2000 Sep;20(18):6860-71.

50.

Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis.

Zhang H, Cook J, Nickel J, Yu R, Stecker K, Myers K, Dean NM.

Nat Biotechnol. 2000 Aug;18(8):862-7.

PMID:
10932156

Supplemental Content

Support Center